ArticleOncoimmunology
Increased infiltration of M2-macrophages, T-cells and PD-L1 expression in high grade leiomyosarcomas supports immunotherapeutic strategies.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 44 citations in OpenAlex.
- Mismatch repair deficiency is rare in bone and soft tissue tumors.Histopathology · 2021Pooled it
- Prognostic Value of Programmed Cell Death 1 Ligand-1 in Patients With Bone and Soft Tissue Sarcomas: A Systemic and Comprehensive Meta-Analysis Based on 3,680 Patients.Frontiers in oncology · 2020Pooled it
- The evolution of cellular therapies in sarcoma: Breakthroughs, challenges, and future directions.Human vaccines & immunotherapeutics · 2026Review
- Precision engineering of macrophage reprogramming with RNA interference-loaded lipid nanoparticles: a game-changer in cancer immunotherapy.Drug delivery and translational research · 2026Review
- Immunotherapy for Leiomyosarcoma: Current Status and Perspectives.Journal of immunology research · 2026Review
- Molecular Heterogeneity in Leiomyosarcoma and Implications for Personalised Medicine.Current treatment options in oncology · 2024Review
- The Future of Targeted Therapy for Leiomyosarcoma.Cancers · 2024Review
- Role of Immunotherapy in Sarcomas.International journal of molecular sciences · 2024Review
- PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates.BMJ case reports · 2023Article
- New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting.Journal of hematology & oncology · 2023Article
- Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy.Scientific reports · 2023Article
- Review
- Macrophage Biomarkers sCD163 and sSIRPα in Serum Predict Mortality in Sarcoma Patients.Cancers · 2023Article
- The Landscape of Immunotherapy for Retroperitoneal Sarcoma.Current oncology (Toronto, Ont.) · 2023Review
- Identification of hub genes correlated with tumor-associated M1-like macrophage infiltration in soft tissue sarcomas.Frontiers in genetics · 2022Article
- Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?Biomedicines · 2021Review
- Tumor and Peripheral Immune Status in Soft Tissue Sarcoma: Implications for Immunotherapy.Cancers · 2021Review
- Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?Cancers · 2021Review
- Influence of tumor-infiltrating immune cells on local control rate, distant metastasis, and survival in patients with soft tissue sarcoma.Oncoimmunology · 2021Article
- When Molecular-Targeted Agents Meet Immunotherapy: The Opportunities for Soft Tissue Sarcoma.Journal of immunotherapy and precision oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.